Evaluating seizures associated with novel antineoplastic agents during breast cancer treatment using the Food and Drug Administration Adverse Event Reporting System and Canada Vigilance Adverse Reaction Online Database
{{output}}
Background: There is a rising incidence of neurological adverse events (AEs), such as seizures, associated with novel anticancer agents, warranting investigation. Large-scale studies assessing seizure risk across diverse anticanc... ...
